JP2018515137A5 - - Google Patents

Download PDF

Info

Publication number
JP2018515137A5
JP2018515137A5 JP2018509977A JP2018509977A JP2018515137A5 JP 2018515137 A5 JP2018515137 A5 JP 2018515137A5 JP 2018509977 A JP2018509977 A JP 2018509977A JP 2018509977 A JP2018509977 A JP 2018509977A JP 2018515137 A5 JP2018515137 A5 JP 2018515137A5
Authority
JP
Japan
Prior art keywords
antibody
cancer
seq
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018509977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515137A (ja
JP6987742B2 (ja
Filing date
Publication date
Priority claimed from EP15305695.7A external-priority patent/EP3091033A1/en
Application filed filed Critical
Publication of JP2018515137A publication Critical patent/JP2018515137A/ja
Publication of JP2018515137A5 publication Critical patent/JP2018515137A5/ja
Application granted granted Critical
Publication of JP6987742B2 publication Critical patent/JP6987742B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018509977A 2015-05-06 2016-05-02 抗ヒトher3抗体及びその使用 Expired - Fee Related JP6987742B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305695.7 2015-05-06
EP15305695.7A EP3091033A1 (en) 2015-05-06 2015-05-06 Anti-human-her3 antibodies and uses thereof
PCT/EP2016/059739 WO2016177664A1 (en) 2015-05-06 2016-05-02 Anti-human-her3 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2018515137A JP2018515137A (ja) 2018-06-14
JP2018515137A5 true JP2018515137A5 (https=) 2019-05-30
JP6987742B2 JP6987742B2 (ja) 2022-01-05

Family

ID=53059029

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018509977A Expired - Fee Related JP6987742B2 (ja) 2015-05-06 2016-05-02 抗ヒトher3抗体及びその使用

Country Status (12)

Country Link
US (1) US11001634B2 (https=)
EP (2) EP3091033A1 (https=)
JP (1) JP6987742B2 (https=)
CN (1) CN107771183A (https=)
BR (1) BR112017023874A2 (https=)
CA (1) CA2985143C (https=)
ES (1) ES2905531T3 (https=)
PL (1) PL3292154T3 (https=)
PT (1) PT3292154T (https=)
RS (1) RS62912B1 (https=)
RU (1) RU2017138468A (https=)
WO (1) WO2016177664A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CN110724194B (zh) * 2018-07-17 2021-03-19 上海生物制品研究所有限责任公司 抗her3人源化单克隆抗体及其制剂
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
GB201913079D0 (en) * 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules
CN113135995B (zh) * 2020-01-17 2022-08-12 上海生物制品研究所有限责任公司 抗her3单克隆抗体及其应用
EP4257153B1 (en) * 2020-12-04 2025-11-12 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof
AU2022293634A1 (en) * 2021-06-15 2024-01-18 Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
MX2024009174A (es) * 2022-01-25 2024-08-09 Medilink Therapeutics Suzhou Co Ltd Anticuerpo contra her3, conjugado y uso del mismo.
CN115724979B (zh) * 2022-10-13 2025-09-30 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
CN116444672B (zh) * 2023-06-13 2023-11-03 上海偌妥生物科技有限公司 人表皮生长因子3的抗体、其制备方法及其应用
WO2025248097A2 (en) * 2024-05-31 2025-12-04 Gamamabs Pharma Humanized anti-human her3 antibodies and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
DE69832158T2 (de) 1997-02-25 2006-08-10 Arizona Board Of Regents, Tempe Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
CN1997382A (zh) 2004-05-05 2007-07-11 梅里麦克制药股份有限公司 调节生物活性的双特异性结合剂
CN101039958A (zh) * 2004-07-21 2007-09-19 格利科菲公司 含有主要是man3glcnac2糖形的免疫球蛋白
CA2599606A1 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
MA33892B1 (fr) * 2009-12-22 2013-01-02 Roche Glycart Ag Anticorps anti-her3, et leurs utilisations
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
EP2617730B1 (en) * 2010-09-17 2018-03-07 National Institute of Advanced Industrial Science And Technology Lung cancer differential marker
KR102101806B1 (ko) * 2011-05-19 2020-04-20 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-인간-her3 항체 및 이의 용도
US9180185B2 (en) * 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
JP6519087B2 (ja) * 2013-06-21 2019-05-29 ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. カロチノイド化合物の異性体比の維持のための新規方法
CA2929386C (en) * 2013-11-07 2023-01-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neuregulin allosteric anti-her3 antibody

Similar Documents

Publication Publication Date Title
JP2018515137A5 (https=)
RU2017138468A (ru) Антитела против человеческого her3, имеющие низкое содержание фукозы, и области их применения
RU2014138039A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2014138040A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2014138038A (ru) Фармацевтическая композиция для лечения профилактики рака
JP2021531254A5 (https=)
JP2020500003A5 (https=)
RU2014138041A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
JP2013544756A5 (https=)
JP2017506217A5 (https=)
JP2018524300A5 (ja) 組成物、抗体および結合性フラグメント
HRP20180507T1 (hr) Identifikacija antigena povezanih s tumorom za dijagnozu i terapiju
JP2014530017A5 (https=)
JP2018509390A5 (https=)
FI3805268T3 (fi) Vasta-aine joka sitoo ErbB-2:ta ja ErbB-3:a
HRP20201022T1 (hr) Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
HRP20192280T1 (hr) Anti-ceacam6 protutijela i njihova uporaba
JP2017507118A5 (https=)
RU2014138474A (ru) Новые модуляторы и способы применения
JP2017149720A5 (https=)
HRP20180262T1 (hr) Monoklonska anti-gt468 protutijela za liječenje karcinoma
RU2018122629A (ru) Антитела против 5t4 и конъюгаты антитело-лекарственное средство
WO2016022939A8 (en) Human monoclonal antibodies specific for 5t4 and methods of their use
HRP20231514T1 (hr) Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka